Roberto Rinaldi

Dr. Roberto Rinaldi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
FDFrancesco Dondi
Francesco Dondi
PBPietro Bellini
Pietro Bellini
MCMichela Cossandi
Michela Cossandi
LCLuca Camoni
Luca Camoni
RRRoberto Rinaldi
Roberto Rinaldi
FBFrancesco Bertagna
Francesco Bertagna
Background/Objectives: Pulmonary lymphangitic carcinomatosis (PLC) is a rare, aggressive manifestation of metastatic cancer characterized by lymphatic infiltration of the lungs, typically indicating advanced disease and poor prognosis. Methods: This comprehensive narrative review evaluates the role of [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) imaging in assessing PLC. Results: Current evidence demonstrates that [18F]FDG PET/CT achieves high diagnostic accuracy, with sensitivity and specificity ranging from 86 to 97% and 84 to 100%, respectively, particularly when employing semiquantitative metrics such as peritumoral standardized uptake value (SUVmax) thresholds (e.g., ≥2.1). PET/CT surpasses high-resolution computed tomography (HRCT) in distinguishing PLC from mimics like pulmonary sarcoidosis by identifying distinct metabolic patterns: bronchovascular hypermetabolism in PLC versus subpleural nodular uptake in sarcoidosis. Prognostically, metabolic tumor burden (e.g., SUVmax × involved lobes) and novel cPLC classifications (localized to the ipsilateral or contralateral lung) independently predict progression-free survival. However, challenges persist, including non-specific tracer uptake in inflammatory conditions and variability in SUV measurements due to technical factors. Emerging digital PET/CT systems, with enhanced spatial resolution, may improve the detection of focal PLC and reduce false negatives. While [18F]FDG PET/CT is invaluable for whole-body staging, therapeutic monitoring and biopsy guidance, the standardization of protocols and multicenter validation of prognostic models are critical for clinical integration. Future research should explore novel tracers (e.g., PSMA for prostate cancer-related PLC) and machine learning approaches to refine diagnostic and prognostic accuracy. Conclusions: This review underscores the role and the transformative potential of [18F]FDG PET/CT in PLC management while advocating for rigorous standardization to maximize its clinical utility.

25 August 2025 in Medicina
Verified
Journal Article
Open access
PDF file
FDFrancesco Dondi
Francesco Dondi
PBPietro Bellini
Pietro Bellini
RGRoberto Gatta
Roberto Gatta
LCLuca Camoni
Luca Camoni
RRRoberto Rinaldi
Roberto Rinaldi
FBFrancesco Bertagna
Francesco Bertagna
Background/Objectives: Cardiac sarcoidosis (CS) is an inflammatory cardiomyopathy with a strong clinical impact on patients affected by the disease and a challenging diagnosis. Methods: This comprehensive narrative review evaluates the role of [18F]fluorodesoxyglucose ([18F]FDG) positron emission tomography (PET)-based radiomics and machine learning (ML) analyses in the assessment of CS. Results: The value of [18F]FDG PET-based radiomics and ML has been investigated for the clinical settings of diagnosis and prognosis of patients affected by CS. Even though different radiomics features and ML models have proved their clinical role in these settings in different cohorts, the clear superiority and added value of one of them across different studies has not been demonstrated. In particular, textural analysis and ML showed high diagnostic value for the diagnosis of CS in some papers, but had controversial results in other works, and may potentially provide prognostic information and predict adverse clinical events. When comparing these analyses with the classic semiquantitative evaluation, a conclusion about which method best suits the final objective cannot be drawn with the available references. Different methodological issues are present when comparing different papers, such as image segmentation and feature extraction differences that are more evident. Furthermore, the intrinsic limitations of radiomics analysis and ML need to be overcome with future research developed in multicentric settings with protocol harmonization. Conclusions: [18F]FDG PET-based radiomics and ML show preliminary promising results for CS evaluation, but remain investigational tools since the current evidence is insufficient for clinical adoption due to methodological heterogeneity, small sample sizes, and lack of standardization.

5 October 2020 in Journal of Nuclear Medicine Technology
Verified
Journal Article
Open access
PDF file
RRRoberto Rinaldi
Roberto Rinaldi
LCLuca Camoni
Luca Camoni
Domenico AlbanoDomenico Albano
Domenico Albano
Respiratory motion artifacts may affect interpretation of whole-body 18F-FDG PET/CT scans, especially when lesions are localized between the liver and the lung. We report a case of a patient with breast cancer who underwent PET/CT after therapy and in whom focal 18F-FDG uptake of equivocal interpretation was observed between the liver and the pleura. A subsequent imaging acquisition of the right lateral decubitus showed that the lesion had a pleural location, thus improving the diagnostic accuracy of the PET/CT finding.

24 April 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
FDFrancesco Dondi
Francesco Dondi
PBPietro Bellini
Pietro Bellini
AMAlberto Miceli
Alberto Miceli
SLSilvia Lucchini
Silvia Lucchini
GVGian Luca Viganò
Gian Luca Viganò
FBFrancesco Bertagna
Francesco Bertagna
[18F]fluoromisonidazole ([18F]FMISO) positron emission tomography (PET) imaging has been explored for its potential use as an added modality for the assessment of gliomas. The aim of this review was to synthesize the existing literature investigating this topic. A comprehensive search of the PubMed/MEDLINE, Scopus, and Embase databases was performed to identify eligible original research investigating the role of [18F]FMISO PET imaging for the evaluation of gliomas. Thirty-tree studies were included in the present review. Overall, the findings reported suggest that [18F]FMISO PET may have relevant clinical implications in glioma assessment and management, including improved tumor characterization, differential diagnosis between different grades and other neoplasms, prognostic stratification, and potential guidance for personalized therapeutic strategies. The available evidence supports the idea that [18F]FMISO PET can act as a robust and biologically meaningful imaging modality in gliomas. Its strengths lie in tumor grading, prognostication, and treatment monitoring, particularly in glioblastoma. Future research should focus on standardized imaging protocols, integration with molecular classification frameworks, and validation of hypoxia-guided therapeutic strategies.

29 June 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
LCLuca Camoni
Luca Camoni
FDFrancesco Dondi
Francesco Dondi
APAgata Pietrzak
Agata Pietrzak
RRRoberto Rinaldi
Roberto Rinaldi
FTFrancesca Tomasoni
Francesca Tomasoni
FBFrancesco Bertagna
Francesco Bertagna
Amyloid PET is increasingly used to confirm cerebral amyloid burden, but standard acquisition may be compromised by head motion, limited patient cooperation, reduced effective counts, premature scan termination, or non-repeatable imaging conditions. This comprehensive narrative review used a structured evidence-mapping approach in accordance with SANRA quality criteria. A structured literature search was performed in PubMed/MEDLINE, Scopus, and Web of Science up to 15 March 2026. Eligible studies included clinical, phantom, or hybrid studies addressing acquisition-time reduction, injected-activity reduction or low-count imaging, motion correction, or artificial intelligence-based image enhancement. Findings were synthesized narratively because of substantial heterogeneity in tracers, scanners, protocols, reconstruction methods, populations, comparators, and endpoints. Sixteen studies were included. Moderate reductions in acquisition time or effective counts generally preserved semiquantitative performance, whereas visual interpretation became more vulnerable under more aggressive reductions, borderline amyloid status, or reduced image quality. Artificial intelligence-based restoration improved image-quality metrics and supported interpretation of short- or low-count acquisitions, but evidence remained model-specific. Motion correction was supported by one amyloid-specific [18F]flutemetamol PET/CT study and should be interpreted as a potentially useful but under-replicated strategy. Current evidence supports cautious, tracer-, scanner-, reconstruction-, and task-specific optimization under challenging acquisition conditions rather than universal protocol reduction or direct generalization to motion-prone, poorly cooperative, or non-repeatable acquisition scenario. Reduced protocols, artificial intelligence-based restoration, and motion correction should remain locally validated supportive strategies, not substitutes for standard acquisition.

11 April 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
FDFrancesco Dondi
Francesco Dondi
PBPietro Bellini
Pietro Bellini
MBMattia Bertoli
Mattia Bertoli
GVGian Luca Viganò
Gian Luca Viganò
RRRoberto Rinaldi
Roberto Rinaldi
FBFrancesco Bertagna
Francesco Bertagna
Background: Evidence on the presence of an association between epicardial adipose tissue (EAT) and myocardial perfusion imaging (MPI) as assessed by positron emission tomography (PET) has been reported. This systematic review aimed to synthesize the existing literature investigating this topic. Methods: A comprehensive and systematic search of the PubMed/MEDLINE, Scopus, and Embase databases was performed to identify published studies investigating the association between EAT and myocardial perfusion assessed by PET imaging. Eligible studies included original research articles evaluating EAT and reporting PET MPI outcomes. Data regarding the study design, patient characteristics, imaging protocols, and main findings were extracted and qualitatively analyzed. Results: Ten studies were included in the final analysis. Overall, most studies demonstrated a significant association between increased EAT and impaired myocardial perfusion on PET imaging. In several studies, EAT remained an independent predictor of abnormal PET MPI after adjustment for traditional clinical risk factors. Nonetheless, important methodological differences among studies were observed, including heterogeneity in EAT measurement techniques, quantification methods, and PET tracers used for MPI evaluation, which limit the generalizability of these findings. Conclusions: This systematic review seems to suggest a potential association between increased EAT and impaired myocardial perfusion, as assessed by PET. However, significant methodological heterogeneity across the available studies—including differences in EAT quantification, PET protocols, and tracer selection—limits the strength of this conclusion. Standardized imaging protocols and larger, prospective, multicenter studies are required to validate this relationship, determine its incremental prognostic value, and evaluate its potential for integration into routine clinical risk stratification pathways.